Thank you very much, Madam Co-Chair.
I'd like to start my questions with Dr. Masuda.
Thank you so much for joining our committee and helping guide us through this topic. I want to expand on your opening statement in which you were talking about the patients you have helped treat with psilocybin therapy.
For full disclosure to my honourable committee members, I did write a letter of support for that section 56 exemption, because I think new and innovative treatments are necessary.
Dr. Masuda, I know that in a previous exchange with Dr. Fry, she did say that it is not a cure-all. I am just wondering if you could maybe expand a bit on the potential promise that it holds. For instance, are we just on the tip of the iceberg of what this potentially could mean for interventions?